← Human Trials & Peer-Reviewed Studies
Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study
Plain-language guide to PMID 19493408 (2009): placebo-controlled randomized controlled trial study of Thymosin Alpha-1 in 114 patients.
Key Facts
- PMID
- 19493408
- Journal
- Chinese medical journal
- Year
- 2009
- Study type
- Randomized Controlled Trial
- Authors
- Chen H et al. (3 authors)
What This Study Did, in Plain Language
What Was Tested
Researchers studied Thymosin Alpha-1 in this randomized controlled trial publication.
Who Took Part
The study group was 114 patients.
PubMed indexes the participants as adults and middle-aged adults, both men and women.
A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard.
All patients had severe sepsis and received standard supportive care and antimicrobial therapy.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
The patients were allocated by chance, so the Thymosin Alpha-1 group and the comparison group should start out alike.
A placebo (an inactive look-alike) gave the Thymosin Alpha-1 group a baseline to be compared against.
Fifty-nine patients were also administered UTI plus Talpha1 (defined as Group A), 55 patients were given a placebo (defined as Group B).
Clinical parameters were determined by evaluation with the Acute Physiology and Chronic Health Evaluation II (APACHE II), multiple organ failure (MOF) and the Glasgow Coma Scores (GCS) on entry and after therapy on the 3rd, 8th, and 28th day.
By flow cytometery and ELISA lymphocyte subsets and cytokines were analyzed.
Survival analysis was determined by the Kaplan-Meier method at 28, 60, and 90 days.
What Was Measured
Topics PubMed links to this paper include Adjuvants, Immunologic, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Glycoproteins, Interleukin-10, Interleukin-6 and Lymphocyte Subsets.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Thymosin Alpha-1 in 114 patients.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2009 (Chinese medical journal), a journal based in China.
More context: the Thymosin Alpha-1 compound page, all human trials.
Our Notes on the Compound
Thymosin Alpha-1: An immune-modulating thymic peptide that recalibrates T-cell function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.